OsteoGeneX is developing a first in class bone building small molecule against the validated target Sclerostin.
OsteoGeneX possesses both near term accelerated clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics.
OstéoQC Closes Seed Financing Round07-Nov-2014
OsteoQC Closes Seed Financing Round Montreal (Nov11, 2014) ..
Invest Midwest 201301-Apr-2013
OsteoGeneX was selected as one of forty companies to present to Midwestern Angels and Venture Ca..
OSTEOGENEX ANNOUNCES ISSUANCE OF A U.S. PATENT COVERING ANTI-SCLEROSTIN BISPHOSPHONATE COMBINATION T01-Jun-2012
OsteoGeneX, a Kansas City, Kansas-based pharmaceutical company, is focused on commercializing or..